Knowing the structure of vitronectin enables rational drug design.
Scientists at Sanford Burnham Prebys have identified the long-sought structure of an essential blood protein: Vitronectin. Knowing the protein’s structure—an advance that enables rational drug design—could lead to medicines that kill multi-drug-resistant bacteria, halt cancer metastasis, treat age-related macular degeneration (AMD) and more. The study was published in Science Advances.
propeller, yielding new insights into its function in the body.
Right: A negatively charged center (red) allows Vitronectin to clasp a
positively charged calcium atom.
“For decades, scientists have speculated about the shape of Vitronectin, but no one had a true answer,” says Francesca Marassi, PhD, senior author of the study and professor at Sanford Burnham Prebys’ NCI-designated Cancer Center. "Our findings provide a blueprint for understanding and targeting this important human protein."
Since Vitronectin’s discovery in the 1960s, scientists recognized that the protein is an important drug target and sought to decipher its complex structure. The protein regulates many fundamental processes, including blood clotting, immunity, tissue development and cell attachment. When these functions are disrupted, disease can arise: Deadly tumor metastasis occurs when cancer cells gain the ability to spread through the body, and pathogens such as Y. pestis (plague), H. influenzae (pneumonia, meningitis), N. gonorrhoeae (gonorrhea) and H. pylori (stomach ulcers), hijack Vitronectin to evade detection by our immune system. However, without a 3D structure, understanding of the protein’s precise function in the body and the ability to design medicines that block or enhance this function were limited.
To visualize the protein’s structure, Marassi and her team analyzed evolutionary clues and then turned to X-rays and magnetic resonance, an MRI-like technology. The researchers found that the functional site of Vitronectin forms a four-bladed propeller with a negatively charged center that binds calcium. This work revealed the binding site of the protein Ail, which Y. pestis bacteria use to hijack Vitronectin and evade the immune system—an important insight for antibiotic drug development in the event plague becomes antibiotic resistant or is ever weaponized.
"Now we see why Vitronectin has so many 'jobs' in the body," explains Marassi. "The propeller acts as a hub for multiple biological activities. The protein’s overall shape and its negatively charged center provide additional insights about its cholesterol and calcium binding properties.”
"The many faces of Vitronectin continue to amaze," says Erkki Ruoslahti, MD, PhD, distinguished professor at Sanford Burnham Prebys, who discovered the protein's adhesive properties and named it 'Vitronectin' based on its ability to stick to glass surfaces. "The first function assigned to Vitronectin was that cells in our blood and tissues attach to it, but it has since turned out to have many other functions. The Vitronectin structure that the Marassi team reports is an important milestone. They show that the bacteria that cause plague bind Vitronectin at a site different from that previously known for cell attachment, suggesting that bacteria use Vitronectin as a bridge to bind human host cells and enhance their infective powers."
Having the structure of Vitronectin in hand is already revealing new insights into human disease. With this information, Marassi made the connection that the shape of Vitronectin correlates with its known involvement in AMD, a condition marked by progressive loss of sight.
"AMD is linked with the accumulation of spherical deposits in the eye. The composition of the spheres—a core of cholesterol, covered by a shell of calcified bone and a topcoat of Vitronectin—aligns perfectly with the protein’s structure that we determined," says Marassi. "I’m already working with scientists at the Institute’s Prebys Center for Drug Discovery to identify drugs that might provide a treatment for AMD."
###
The first authors of the study are Kyungsoo Shin, PhD, at SBP, and Bernhard C. Lechtenberg, PhD, formerly at SBP and currently at the Water & Eliza Hall Institute of Medical Research, who each contributed equally to the work.
Additional authors include Lynn M. Fujimoto, BS, and Yong Yao, PhD, at SBP; and Sara Schesser Bartra, PhD, and Gregory V. Plano, PhD, at the University of Miami Miller School of Medicine.
The study’s DOI is eaax5068.
Research reported in this press release was supported by the U.S. National Institutes of Health (NIH) (GM118186, AI130009, P30CA030199) and the Canadian Institutes of Health Research. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.